🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

RadNet, Inc. RDNT R2KR3KPHARMA

Healthcare · Diagnostics & Research · United States
https://www.radnet.com
Company Profile ↓
$73.71
+7.75% 1Y
Mkt Cap$5.80B
P/E-433.59
P/B5.26
52W High$84.48
52W Low$51.87
Book Value$13.76
EPS (TTM)$-0.17

Company Overview

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $2.04B (+11.5% YoY); net profit $-18.65M.
  • Trailing 12 Months Year-on-year growth — revenue +22.1%, earnings -767.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 8.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:8.82%
1 Year:22.10%

Compounded Profit Growth

5 Years:-
1 Year:-767.81%

Stock Price Performance

1 Year:+7.75%
6 Months:+21.47%
3 Months:+35.65%
1 Month:+8.14%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 67% of range
$51.87 $84.48
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross8d ago
  • RSI (14)52.50 · Neutral
Price Performance
1M+8.14%
3M+35.65%
6M+21.47%
1Y+7.75%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-433.59
Industry PE
25.17
Forward P/E
78.14
PEG Ratio
0.96
Book Value
$13.76
Price to Book
5.26
P/S
2.65
EV/EBITDA
29.43
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
8.82%
Profit 5Y
-
Revenue (YoY)
22.10%
Earnings (YoY)
-767.81%

Profitability & Returns

ROCE
1.95%
ROE
1.77%
ROA
1.58%
Profit Margin
-0.66%
Op Margin
-2.85%
Gross Margin
17.20%
EPS (Latest Qtr)
$0.10
EPS (TTM)
$-0.17

Balance Sheet & Liquidity

Debt/Equity
1.43
Quick Ratio
1.05
Current Ratio
1.17
Debt
$1.93B
Total Assets
$4.23B
Current Assets
$740.77M
Working Capital
$445.36M

Ownership

Promoter Holding
9.96%
Chg in Prom Hold
-0.01%
FII / Inst Holding
105.07%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$5.80B
Total Revenue (TTM)
$2.14B
EBITDA
$252.91M
Free Cash Flow
$190.47M
Operating Cash Flow
$336.31M
Shares Outstanding
78.63M
Gross Margin
17.20%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 RDNT RadNet, Inc. R2KR3KPHARMA 73.71 -433.59 $5.80B 0.00% 1.95% 1.77% 8.82% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue -----------------289.10M292.69M-281.56M190.57M291.78M315.32M333.92M332.69M341.77M354.38M350.04M390.56M403.71M401.97M431.71M459.71M461.14M471.40M498.23M522.87M575.63M622.72M
Operating Income -1.95M13.38M17.23M-2.98M8.08M12.45M-6.75M14.16M10.84M--888.00K15.87M16.45M-7.27M21.98M16.85M--8.78M179.00K23.38M17.65M27.68M32.57M-1.72M19.56M6.92M6.67M24.44M43.25M11.34M34.85M33.91M-24.10M30.88M27.39M-23.90M39.47M
Net Income -4.55M3.40M7.99M881.00K-1.72M3.62M1.65M3.68M-1.21M5.31M3.23M-7.28M-7.34M5.41M5.04M29.14M-3.73M4.90M3.19M10.40M-16.36M-10.59M6.16M9.46M2.87M16.22M3.01M7.91M668.00K-21.00M8.37M17.54M-2.78M-2.98M3.21M-37.93M14.45M5.42M-33.47M7.53M
Diluted EPS -0.110.080.180.02-0.040.080.040.08-0.030.110.07-0.15-0.150.110.100.59-0.080.100.060.21-0.33-0.210.120.180.050.300.050.130.01-0.360.120.25-0.04-0.040.04-0.510.190.07-0.430.10

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 527.62M76.94M76.08M85.04M702.99M717.57M809.63M884.53M922.19M975.15M1.15B1.07B1.32B1.43B1.62B1.83B2.04B
Operating Income 42.10M41.71M50.66M12.64M43.60M53.30M39.12M38.48M50.05M30.89M69.88M35.68M82.55M46.36M98.70M104.62M61.99M
Net Income -2.27M-12.85M7.23M12.39M2.12M1.38M7.71M7.23M53.00K32.24M14.76M-14.84M24.73M10.65M3.04M2.79M-18.65M
Diluted EPS -0.06-0.350.191.520.050.030.170.150.000.660.29-0.290.460.170.050.04-0.25

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --539.51M619.19M710.86M40.65M740.68M836.43M849.48M868.98M1.11B1.65B1.79B-2.43B2.69B3.29B3.76B
Current Assets --------------367.18M579.28M1.02B1.03B
Cash & Equivalents -10.09M627.00K2.09M362.00K8.41M307.00K446.00K20.64M51.32M10.39M40.16M102.02M-127.83M342.57M740.02M767.22M
Inventory ------------------
Receivables --------------166.36M163.71M185.82M200.32M
Total Liabilities --621.99M689.00M717.55M5.64M732.98M799.97M797.42M799.05M909.08M1.41B1.53B-1.94B1.88B2.15B2.40B
Current Liabilities --105.26M122.38M119.04M2.98M133.27M156.96M155.34M191.61M239.52M327.43M398.11M-466.72M437.45M479.71M586.76M
Long Term Debt ---543.19M573.76M575.45M572.50M607.61M612.17M575.04M--612.91M-839.34M812.07M991.57M1.06B
Total Debt --------------1.51B1.49B1.73B1.86B
Total Equity -81.03M-74.76M-82.47M-69.81M-6.68M-80.00K7.70M36.46M52.05M61.56M127.18M151.69M165.74M-333.00M630.70M902.31M1.09B
Shares Outstanding --------------57.72M67.96M74.04M77.40M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 76.62M66.88M57.64M75.27M66.42M-67.04M91.64M142.22M116.75M104.32M233.76M149.49M146.42M220.86M233.02M298.82M
Investing Cash Flow -36.28M-101.38M-87.74M-87.05M-50.66M--96.80M-65.49M-79.32M-146.75M-99.47M-126.24M-221.51M-246.95M-201.47M-233.07M-343.87M
Financing Cash Flow -30.24M25.04M31.93M9.62M-7.62M-29.94M-5.91M-32.25M-10.87M24.95M-45.56M104.67M93.65M195.63M397.95M72.21M
Capital Expenditure -30.75M-40.29M-42.72M-1.09M-48.62M-41.74M-42.96M-59.25M-61.34M-72.18M-74.15M------
Free Cash Flow 45.87M26.59M14.92M74.18M17.80M-24.07M32.39M80.89M44.57M30.17M------

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------
Operating Margin % 8.0%54.2%66.6%14.9%6.2%7.4%4.8%4.4%5.4%3.2%6.1%3.3%6.3%3.2%6.1%5.7%3.0%
Net Margin % -0.4%-16.7%9.5%14.6%0.3%0.2%1.0%0.8%0.0%3.3%1.3%-1.4%1.9%0.7%0.2%0.2%-0.9%
ROE % 3.0%15.6%-10.4%-185.4%-2,650.0%17.9%21.1%13.9%0.1%25.4%9.7%-9.0%-3.2%0.5%0.3%-1.7%
ROCE % -9.6%10.2%2.1%115.8%8.8%5.8%5.5%7.4%3.6%5.3%2.6%-2.4%4.4%3.7%2.0%

Shareholding Pattern

Insiders
9.96%
Institutions
105.07%
Public Float
116.69%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 13.92% 10.96M $817.56M
2 RTW Investments LP 6.16% 4.85M $361.63M
3 Price (T.Rowe) Associates Inc 5.72% 4.50M $335.83M
4 Vanguard Portfolio Management LLC 5.17% 4.07M $303.43M
5 Vanguard Capital Management LLC 4.06% 3.19M $238.27M
6 Beck, Mack & Oliver LLC 4.02% 3.16M $236.04M
7 State Street Corporation 3.61% 2.84M $212.08M
8 Geode Capital Management, LLC 2.36% 1.86M $138.66M
9 Invesco Ltd. 2.09% 1.64M $122.46M
10 American Century Companies Inc 2.06% 1.62M $120.75M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RDNT

Yahoo Finance Wed, 02 Sep 2026

3 of Wall Street’s Favorite Stocks We Find Risky

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly …

Yahoo Finance ue, 11 Aug 2026

RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised

RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.

Yahoo Finance Mon, 10 Aug 2026

RadNet Inc (RDNT) (Q2 2026) Earnings Call Highlights: Record Revenue and AI-Driven Growth ...

RadNet Inc (RDNT) posts 25% revenue surge to $622.7 million, with AI revenue soaring 136% and advanced imaging volumes driving record adjusted EBITDA.

Yahoo Finance Mon, 10 Aug 2026

RadNet (RDNT) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for RadNet (RDNT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.…

Yahoo Finance Mon, 10 Aug 2026

Is RadNet (RDNT) Undervalued As AI Growth Hopes Push The Stock Higher?

Recent trading action and performance snapshot RadNet (RDNT) has drawn investor attention after recent trading, with the stock closing at US$72.39 on 4 August 2026. That closing price implies a market value of about US$5.69b. Over the past …

Yahoo Finance Wed, 26 Aug 2026

Nano-X Imaging (NNOX) Is 'One to Watch'

The company combines proprietary imaging hardware, FDA-cleared AI applications, cloud software, radiology services and healthcare IT within an end-to-end platform spanning scan, analysis and interpretation. Nanox is expanding its commercial…

RDNT — Frequently Asked Questions

What is the current share price of RadNet, Inc. (RDNT)?

As of 2026-09-07 16:24 PDT, RadNet, Inc. (RDNT) trades at $73.71 on NasdaqGM. Its 52-week range is $51.87 to $84.48.

What is the market capitalisation of RDNT?

RadNet, Inc. (RDNT) has a market capitalisation of $5.80B on NasdaqGM.

What is the P/E ratio of RDNT?

RDNT trades at a trailing price-to-earnings (P/E) ratio of -433.59. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.26.

What is the return on equity (ROE) of RDNT?

RDNT has a return on equity (ROE) of 1.77%. Its return on capital employed (ROCE) is 1.95%.

Is RDNT a good stock to buy?

This page provides a data-driven analysis of RadNet, Inc. (RDNT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space